Breast Cancer

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

Scott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.

Second-generation immuno-oncology studies hold great promise for breaking through the known barriers highlighted by earlier research against metastatic breast cancer.

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the presence of PIK3CA mutations and ESR1 mutations in patients with breast cancer enrolled in the phase III MONARCH 2 trial.

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.

Advancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.

Mariana Chavez Mac Gregor, MD, MSc, discussex recent shifts in the treatment of patients with metastatic triple-negative breast cancer.

Joyce A. O’Shaughnessy, MD, co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, Texas Oncology, chair of The US Oncology Network, and 2016 Giant of Cancer Care® in Community Outreach, discusses the clinical implications of the TEXT and SOFT trials in premenopausal women with hormone receptor-positive breast cancer.

We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.

The European Commission has approved olaparib (Lynparza) for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.

For women at average risk for breast cancer who are between the ages of 40 and 49 years, clinicians should have a personalized approach on whether their patients should be screened with mammography prior to the age of 50.

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

This year we are celebrating the 20th anniversary of our flagship publication OncologyLive. To mark the occasion, we are asking oncology leaders to reflect on the tremendous progress made in cancer research and practice over the past 2 decades.

The FDA has expanded the approval of palbociclib capsules in combination with endocrine therapy for male patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.

Primary tumor surgery for patients with stage IV HER2-positive breast cancer is associated with an improvement in overall survival, according to results of a retrospective cohort review presented at the 2019 AACR Annual Meeting.

A majority of patients with large triple-negative breast tumors achieved pathologic complete response when treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy.